Announced that informed consent obtained exceeded the target enrollment. Will steadily proceed with subject enrollment and focus on executing the WAKABA trial. No impact on full-year results for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Ribomic Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4591-20261022-01.pdf","jir_short_summary":"Announced that informed consent obtained exceeded the target enrollment. Will steadily proceed with subject enrollment and focus on executing the WAKABA trial. No impact on full-year results for the fiscal year ending March 2027.","jir_summary":"### Clinical Trial Progress and Drug Development Status\nRibomic Inc. is conducting a domestic Phase III clinical trial (WAKABA trial) in pediatric patients with achondroplasia (ACH) using umsptanib pegol (international nonproprietary name for RBM-007). The company announced that it has obtained informed consent from trial participants exceeding the target enrollment. Going forward, eligibility confirmations and required washout periods for concomitant medications will be completed and registrations will proceed, with focus on successful conduct of the trial. This matter will not affect the full-year results for the fiscal year ending March 2027.\n\n### Upcoming Schedule and Positioning of the Drug\nAmid multiple ACH treatments under development, the early attainment of consents indicates expectations for this drug. The company will steadily advance subject enrollment and aims to continue and complete the trial. The drug is positioned as an orphan drug candidate that functions as an aptamer inhibiting FGF2 and may directly act on FGFR3-related pathophysiology.","jir_financial_highlights":"Impact: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Ribomic, #ClinicalTrialProgress, #ACHtherapeutics","jir_key_figures":"Target number of enrolled subjects: 16 people (target stated in the text)\nNumber of informed consents obtained: Exceeded target\nImpact on full-year results for fiscal year ending March 2027: Unknown \u2192 No impact","jir_meta_title":"Ribomic Inc. - Domestic Phase III Progress for ACH Therapy | Informed Consent Exceeds Target","jir_meta_description":"Ribomic Inc. announced that informed consent in the domestic Phase III trial of umsptanib pegol for achondroplasia exceeded the target. The company will focus on advancing subject enrollment and trial conduct. No impact on fiscal 2027 full-year results.","jir_og_title":"Ribomic Inc. - Domestic Phase III Progress for ACH Therapy | Informed Consent Exceeds Target","jir_og_description":"Ribomic Inc. announced that informed consent in the domestic Phase III trial for an achondroplasia treatment exceeded the target. The company will focus on enrollment progress and trial execution; there is no impact on results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-133428","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n